Loading...
•
Jun 30, 2021
Insmed Q2 2021 Earnings Report
Insmed's financial results for Q2 2021 were released, highlighting the launch of ARIKAYCE in Japan and continued progress in clinical development programs.
Key Takeaways
Insmed reported total revenue of $45.4 million for the second quarter of 2021, compared to $42.5 million for the second quarter of 2020. The company's GAAP net loss was $117.3 million, or $1.07 per share, compared to a GAAP net loss of $61.9 million, or $0.64 per share, for the second quarter of 2020. ARIKAYCE was launched in Japan in July 2021.
ARIKAYCE launched in Japan in July 2021, making it available in three major territories.
Enrollment continues in the Phase 3 ASPEN study of brensocatib in patients with bronchiectasis.
Advancement of TPIP to Phase 2 development in both PAH and PH-ILD is ongoing.
Insmed reported total revenue of $45.4 million for the second quarter of 2021.